🔴 XBI is trading 3.27% down today as broad risk-off trading pressures biotech valuations

XBI is trading 3.27% down at $156.58, with broad risk-off trading weighing on biotech valuations.

• The Nasdaq is down 1.00%, while rising crude oil and the 10-year Treasury yield near 4.99% are weighing on growth-oriented biotech valuations.
• Positive biotech developments reported September 22–23 included Amgen’s encouraging clinical update and Boehringer Ingelheim’s potential $1 billion Envisagenics collaboration.
• No XBI-specific negative catalyst was identified.